중국CAR-T치료 관련 연구 현황
페이지 정보
작성자 HK HIS 작성일19-09-16 18:15 조회1,557회 댓글0건관련링크
https://www.researchgate.net/publication/320572177_Clinical_trials_of_…
본문
중국 CAR-T세포 의 임상 현황
Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric
antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells,
tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs
directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells,
simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are
also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell
development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in
China and provided a quick glimpse of the landscape of CAR-T studies in China
